Clinical Trials Logo

HbA1C clinical trials

View clinical trials related to HbA1C.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05584085 Recruiting - Clinical trials for Acceptance and Commitment Therapy

ACT-DE for Diabetes Distress and HbA1c in Adults With Type 2 Diabetes

ACT-DE
Start date: October 15, 2022
Phase: N/A
Study type: Interventional

This study will evaluate the effectiveness of a structured acceptance-based diabetes education programme for adults with type 2 diabetes compared with those who received diabetes education. The programme mainly comprises acceptance and commitment therapy (ACT) as a psychological component and a diabetes education (DE) component. The short form of the programme is named 'ACT-DE'. This programme aims to decrease the diabetes distress level in participants with type 2 diabetes and improve their blood glucose level. The objectives are: 1. To develop an ACT-based intervention protocol as a guide for promoting healthy coping in people with type 2 diabetes who are psychologically distressed. 2. To examine the effects of 'ACT-DE' on diabetes distress and HbA1c (primary outcomes) over a three-month follow-up, when compared with diabetes education only. 3. To examine the effects of 'ACT-DE' on diabetes self-management behaviours, self-efficacy in diabetes care, and psychological flexibility (secondary outcomes) over the three-month follow-up, when compared with diabetes education; and 4. To identify the relationships between psychological flexibility and diabetes self-efficacy, diabetes self-management behaviour and HbA1c among the study participants

NCT ID: NCT04965051 Recruiting - HbA1c Clinical Trials

Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM

Start date: August 2021
Phase: N/A
Study type: Interventional

In this prospective, randomized, open-label, parallel group trial, the safety and efficacy of insulin degludec/insulin aspart (IDegAsp) twice daily will be compared with basal insulin once or twice daily plus pre-prandial insulin after 16 weeks of treatment in patients with type 1 diabetes. This trial will enable assessment of the clinically relevant endpoint of a change in HbA1c and Time in Range (TIR).

NCT ID: NCT04736277 Recruiting - Clinical trials for Neurocognitive Disorders

HbA1c and Neurocognitive Disorders

Start date: December 1, 2015
Phase:
Study type: Observational

Preliminary evidence suggest a possible relationship between HbA1c and perioperative neurocognitive disorders (NCD). We are going to investigate whether the preoperative value of HbA1c in patients undergoing elective non-cardiac surgery under general anesthesia, are related with increased risk of perioperative NCD.